Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
1. A poxvirus expression vector for expressing the BFA4 protein in a cell, the vector comprising the nucleic acid sequence of SEQ ID NO.: 1 and at least one nucleic sequence encoding an angiogenesis-associated antigen, wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein.
2. The expression vector of claim 1 further comprising at least one additional tumor-associated antigen.
3. The expression vector of claim 2 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
4. The expression vector of claim 3 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
5. The expression vector of claim 1 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
6. The expression vector of claim 5 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
7. The expression vector of claim 1 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
8. The expression vector of claim 7 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
9. The poxvirus of claim 8 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
10. A composition comprising the poxvirus expression vector of claim 1 and a pharmaceutically acceptable carrier.
11. The composition of claim 10 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
12. The composition of claim 11 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
13. The expression vector of claim 2 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.
14. The expression vector of claim 2 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
15. A composition comprising the poxvirus expression vector of claim 2 and a pharmaceutically acceptable carrier.
16. The composition of claim 15 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
17. The composition of claim 16 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
18. A poxvirus expression vector comprising a nucleic acid sequence encoding a BFA4 protein having the amino acid sequence of SEQ ID NO:2 and at least one nucleic sequence encoding an angiogenesis-associated antigen, wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein.
19. The expression vector of claim 18 further comprising a nucleic acid encoding at least one additional tumor-associated antigen.
20. The expression vector of claim 19 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
21. The expression vector of claim 20 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
22. The expression vector of claim 18 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
23. The expression vector of claim 22 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
24. The expression vector of claim 18 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
25. The expression vector of claim 24 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
26. The poxvirus of claim 25 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
27. A composition comprising an expression vector of claim 19 and a pharmaceutically acceptable carrier.
28. A composition comprising an expression vector of claim 18 and a pharmaceutically acceptable carrier.
29. The expression vector of claim 7 , 24 , or 14 wherein the co-stimulatory component is B7.1.
30. The expression vector of claim 7 , 24 , or 14 wherein the co-stimulatory component is TRICOM comprising B7.1, LFA-3 and ICAM-1.
31. The expression vector of claim 1 or 18 wherein the angiogenesis-associated antigen is selected from the group consisting of vascular endothelial growth factor, vascular endothelial growth factor receptor EPH receptors, epidermal growth factor receptor, basic fibroblast growth factor, platelet-derived cell growth factor, platelet-derived endothelial cell growth factor, a transforming growth factor, endoglin, an Id proteins, uPA, uPAR, a matrix metalloproteinases, thrombospondin, and surface proteolglycan NG2.
32. The expression vector claim 2 or 19 wherein the at least one additional tumor-associated antigen is selected from the group consisting of gp100, TRP-1, NY-ESO-1, a MAGE antigen, MAGE-1, MAGE-3, carcinoembryonic antigen, MUC-1, and NY-BR-1.